文献速递脑血管病神经重症与神经感染

跳过最近卒中中心对脑出血患者的影响:RACECAT随机临床试验的二次分析

Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage: A Secondary Analysis of the RACECAT Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2023-01-01

该研究为RACECAT试验的预设二次分析,纳入最终诊断为脑出血的患者302例,比较直接转运至具备血管内治疗能力的卒中中心与转运至最近本地卒中中心的效果。结果显示,直接转运至具备血管内治疗能力的卒中中心组90天功能结局更差(调整共同OR 0.63,95%CI 0.41-0.96),且转运途中医疗并发症和院内肺炎发生率更高。

要点

  • 脑出血患者直接转运至具备血管内治疗能力的卒中中心,90天功能结局更差(调整共同OR 0.63,95%CI 0.41-0.96)。
  • 直接转运组90天死亡率似乎更高(48.9% vs 37.6%;调整HR 1.40,95%CI 0.99-1.99)。
  • 直接转运组转运途中医疗并发症(22.6% vs 5.6%;调整OR 5.29,95%CI 2.38-11.73)和院内肺炎(35.8% vs 17.6%;OR 2.61,95%CI 1.53-4.44)更高。

核心结论

  • 在RACECAT随机临床试验的二次分析中,对于最终诊断为脑出血的患者,跳过最近卒中中心直接转运至具备血管内治疗能力的卒中中心,导致90天功能独立的机会降低。

研究设计与样本

  • RACECAT试验的预设二次分析,该试验为多中心、基于人群的整群随机临床试验,2017年3月至2020年6月在西班牙加泰罗尼亚开展,采用盲法终点评估。
  • 纳入所有疑似大血管闭塞卒中(现场Rapid Arterial Occlusion Evaluation Scale [RACE]评分>4分,量表0-9分,分值越高卒中越重)且最终诊断为脑出血的连续患者。
  • 共302例患者纳入分析(204例[67.5%]男性;平均[SD]年龄71.7[12.8]岁;中位[IQR] RACE评分7[6-8]),直接转运至具备血管内治疗能力的卒中中心组137例,转运至最近本地卒中中心组165例。

主要发现

  • 主要结局:直接转运至具备血管内治疗能力的卒中中心组平均[SD] mRS评分4.93[1.38],转运至最近本地卒中中心组平均[SD] mRS评分4.66[1.39];调整共同OR 0.63(95%CI 0.41-0.96),直接转运组90天功能结局更差。
  • 90天死亡率:直接转运组67/137例(48.9%)vs 最近本地卒中中心组62/165例(37.6%);调整HR 1.40(95%CI 0.99-1.99),提示直接转运组90天死亡率可能更高。
  • 转运途中医疗并发症:直接转运组30/137例(22.6%)vs 最近本地卒中中心组9/165例(5.6%);调整OR 5.29(95%CI 2.38-11.73),直接转运组更高。
  • 院内肺炎:直接转运组49/137例(35.8%)vs 最近本地卒中中心组29/165例(17.6%);OR 2.61(95%CI 1.53-4.44),直接转运组更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Prehospital transfer protocols are based on rapid access to reperfusion therapies for patients with ischemic stroke. The effect of different protocols among patients receiving a final diagnosis of intracerebral hemorrhage (ICH) is unknown. OBJECTIVE: To determine the effect of direct transport to an endovascular treatment (EVT)-capable stroke center vs transport to the nearest local stroke center. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified secondary analysis of RACECAT, a multicenter, population-based, cluster-randomized clinical trial conducted from March 2017 to June 2020 in Catalonia, Spain. Patients were evaluated by a blinded end point assessment. All consecutive patients suspected of experiencing a large vessel occlusion stroke (Rapid Arterial Occlusion Evaluation Scale [RACE] score in the field >4 on a scale of 0 to 9, with lower to higher stroke severity) with final diagnosis of ICH were included. A total of 1401 patients were enrolled in RACECAT with suspicion of large vessel occlusion stroke. The current analysis was conducted in October 2022. INTERVENTION: Direct transport to an EVT-capable stroke center (n = 137) or to the closest local stroke center (n = 165). MAIN OUTCOMES AND MEASURES: The primary outcome was tested using cumulative ordinal logistic regression to estimate the common odds ratio (OR) and 95% CI of the shift analysis of disability at 90 days as assessed by the modified Rankin Scale (mRS) score (range, 0 [no symptoms] to 6 [death]) in the intention-to-treat population. Secondary outcomes, included 90-day mortality, death or severe functional dependency, early neurological deterioration, early mortality, ICH volume and enlargement, rate of neurosurgical treatment, rate of clinical complications during initial transport, and rate of adverse events until day 5. RESULTS: Of 1401 patients enrolled, 1099 were excluded from this analysis (32 rejected informed consent, 920 had ischemic stroke, 29 had transient ischemic attack, 12 had subarachnoid hemorrhage, and 106 had stroke mimic). Thus, 302 patients were included (204 [67.5%] men; mean [SD] age 71.7 [12.8] years; and median [IQR] RACE score, 7 [6-8]). For the primary outcome, direct transfer to an EVT-capable stroke center (mean [SD] mRS score, 4.93 [1.38]) resulted in worse functional outcome at 90 days compared with transfer to the nearest local stroke center (mean [SD] mRS score, 4.66 [1.39]; adjusted common OR, 0.63; 95% CI, 0.41-0.96). Direct transfer to an EVT-capable stroke center also suggested potentially higher 90-day mortality compared with transfer to the nearest local stroke center (67 of 137 [48.9%] vs 62 of 165 [37.6%]; adjusted hazard ratio, 1.40; 95% CI, 0.99-1.99). The rates of medical complications during the initial transfer (30 of 137 [22.6%] vs 9 of 165 patients [5.6%]; adjusted OR, 5.29; 95% CI, 2.38-11.73) and in-hospital pneumonia (49 of 137 patients [35.8%] vs 29 of 165 patients [17.6%]; OR, 2.61; 95% CI, 1.53-4.44) were higher in the EVT-capable stroke center group. CONCLUSIONS AND RELEVANCE: In this secondary analysis of the RACECAT randomized clinical trial, bypassing the closest stroke center resulted in reduced chances of functional independence at 90 days for patients who received a final diagnosis of ICH. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02795962.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Ramos-Pachón A, Rodríguez-Luna D, Martí-Fàbregas J, et al. Effect of Bypassing the Closest Stroke Center in Patients with Intracerebral Hemorrhage: A Secondary Analysis of the RACECAT Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37603325. doi:10.1001/jamaneurol.2023.2754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。